Home038290 • KOSDAQ
add
Macrogen Inc
Previous close
₩16,150.00
Day range
₩16,210.00 - ₩16,650.00
Year range
₩14,920.00 - ₩26,700.00
Market cap
174.01B KRW
Avg Volume
62.86K
P/E ratio
-
Dividend yield
1.82%
Primary exchange
KOSDAQ
Market news
Financials
Income Statement
Revenue
Net income
| (KRW) | Sep 2024info | Y/Y change |
|---|---|---|
Revenue | 33.00B | 2.20% |
Operating expense | 13.80B | 4.68% |
Net income | -3.18B | -60.92% |
Net profit margin | -9.64 | -57.52% |
Earnings per share | — | — |
EBITDA | 2.21B | 47.21% |
Effective tax rate | 1.20% | — |
Balance Sheet
Total assets
Total liabilities
| (KRW) | Sep 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 24.60B | 8.61% |
Total assets | 274.19B | 3.79% |
Total liabilities | 124.82B | 40.99% |
Total equity | 149.37B | — |
Shares outstanding | 9.97M | — |
Price to book | 1.09 | — |
Return on assets | -0.54% | — |
Return on capital | -0.70% | — |
Cash Flow
Net change in cash
| (KRW) | Sep 2024info | Y/Y change |
|---|---|---|
Net income | -3.18B | -60.92% |
Cash from operations | -2.08B | 50.99% |
Cash from investing | -9.57B | -22.48% |
Cash from financing | 6.73B | 594.06% |
Net change in cash | -4.51B | 58.99% |
Free cash flow | -10.07B | 35.34% |
About
Macrogen, Inc. is a South Korean public biotechnology company. The company's headquarters are located in Seoul. The company was founded in 1997 by Jeong-sun Seo, a professor at Seoul National University. It was venture capital-backed until its initial public offering and subsequent listing on the KOSDAQ market in 2000, making it the first Korean biotechnology firm to raise funds through an IPO. The company announced plans in 2010 to map the "Korean genome" based on the notion that United States-backed genome mapping efforts up to that time were representative of the "Caucasian genome" rather than the "Human genome" as claimed. By 2015, the company was described by one news outlet as "a global leader in personalized genomic medicine". Wikipedia
Founded
Jun 5, 1997
Website
Employees
532
